



DEPARTMENT OF COMMERCE UNITED STATE

Patent and Trademark Offic COMMISSIONER OF PATENTS AND TRADEMARKS Address:

Washington, D.C. 20231

ATTORNEY DOCKET NO. FIRST NAMED INVENTOR FILING DATE APPLICATION NO. 103.009US1 D CARSON 05/17/99 09/313,048 **EXAMINER** HM12/0118 021186 SCHROEDER. T SCHWEGMAN LUNDBERG WOESSNER & KLUTH PAPER NUMBER

P 0 BOX 2938 MINNEAPOLIS MN 55402

ART UNIT 12

1611 DATE MAILED:

01/18/00

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trad marks

Application No.

Applicant(s) 09/313,048

Carson et al.

Examiner

Office Action Summary

Ben Schroeder

Group Art Unit 1611



Responsive to communication(s) filed on	
☐ This action is FINAL .	
☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213.	
A shortened statutory period for response to this action is set to expi is longer, from the mailing date of this communication. Failure to resapplication to become abandoned. (35 U.S.C. § 133). Extensions of 37 CFR 1.136(a).	pond within the period for response will cause the
Disposition of Claims	
X Claim(s) 1-11, 13-15, 18, and 19	is/are pending in the application.
Of the above, claim(s)	is/are withdrawn from consideration.
X Claim(s) 1-10 and 13-15	is/are allowed.
X Claim(s) 11, 18, and 19	
☐ Claim(s)	
☐ Claims	
Application Papers	
☐ See the attached Notice of Draftsperson's Patent Drawing Revi	ew, PTO-948.
☐ The drawing(s) filed on is/are objected to	by the Examiner.
☐ The proposed drawing correction, filed on is ☐ approved ☐ disapproved.	
☐ The specification is objected to by the Examiner.	
$\hfill\Box$ The oath or declaration is objected to by the Examiner.	
Priority under 35 U.S.C. § 119	
Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).	
☐ All ☐ Some* ☐ None of the CERTIFIED copies of the priority documents have been	
☐ received.	
☐ received in Application No. (Series Code/Serial Number)	
\square received in this national stage application from the International Bureau (PCT Rule 17.2(a)).	
*Certified copies not received:	
☐ Acknowledgement is made of a claim for domestic priority und	er 35 U.S.C. § 119(e).
Attachment(s)	
☑ Notice of References Cited, PTO-892	
☑ Information Disclosure Statement(s), PTO-1449, Paper No(s). ☐ The control of the control	
☐ Interview Summary, PTO-413☐ Notice of Draftsperson's Patent Drawing Review, PTO-948	
☐ Notice of Informal Patent Application, PTO-152	
SEE OFFICE ACTION ON THE FOLLOWING PAGES	

Art Unit: 1611

DETAILED ACTION

Claims 1-11, 13-15, and 18-19 are pending.

Claim Rejections - 35 USC § 112

- 1. The examiner acknowledges the declaration submitted by the applicants of 12/6/99 and agrees that the evidence presented is sufficient to overcome the first paragraph 35 U.S.C. 112 rejection made by the examiner, however the amended claim has a second paragraph of U.S.C. 112 problem as follows.
- 2. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

3. Claims 11, 18, and 19 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Claims 11, 18, and 19 are rejected as being vague and indefinite because it is not known what is meant by 'overproduction of proinflammatory cytokines' (in claim 11). It is not clear to what this 'overproduction' is relative. Clarification is required.

. . .

Art Unit: 1611

Allowable Subject Matter

4. Claims 1-10 and 13-15 are allowed. The reason for the allowable subject matter is as follows: The thiazolopyrimidine compounds claimed are unknown in the chemical art. The closest compounds all have alkyl functionalities at the 3-position of the pyrimidine ring. (For example, see Flammang et al. in J. Am. Chem. Soc. (1994), 116(5), 2005-13.).

Conclusion

5. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ben Schroeder whose telephone number is (703) 306-5815. The examiner can normally be reached on Monday thru Friday from 8:30 AM to 5:00 PM.

Application/Control Number: 09313048

Page 4

Art Unit: 1611

The fax phone number for this Group is (703) 308-4734 for "unofficial" purposes and the actual number for **OFFICIAL** business is **308-4556**.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-1235.

Muxued J. Shel

tbs

Mukund J. Shah

Supervisory Patent Examiner

Art Unit 1611